Research programme : anti-cancer therapies - Vertero Therapeutics
Alternative Names: AB-6000 seriesLatest Information Update: 28 Nov 2025
At a glance
- Originator Axial Biotherapeutics
- Developer Vertero Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Cancer in USA
- 19 Oct 2021 Axial Biotherapeutics in-licenses worldwide rights of intellectual property of central nervous system biotherapeutics from California Institute of Technology
- 19 Oct 2021 Preclinical trials in Cancer in USA (unspecified route) (Axial Biotherapeutics pipeline)